Glycosyn announces the availability for licensing of its commercial high-titer human milk oligosaccharide (HMO) production strains, and IP covering prebiotic, anti-inflammatory and anti-infective uses of HMOs

Waltham, Massachusetts, USA, December 19, 2024 — In a new development announced today, Glycosyn LLC is offering for license its entire portfolio of proprietary high-titer commercial fermentation strains for the production of human milk oligosaccharides (HMOs). Included are strains for the commercial production of 2’-fucosyllactose (2’-FL), Lacto-N-tetraose (LNT), 3’-sialyllactose (3’-SL) and 6’-sialyllactose (6’-SL). Glycosyn’s strains are validated at large scale (>50,000L).

Glycosyn is open to exploring exclusive and non-exclusive global or regional licenses to use these strains for the commercial supply of HMOs in the areas of adult and infant nutrition, food supplements and therapeutics.

HMOs are natural human prebiotics that stimulate the growth of beneficial bacteria in the gut while exhibiting antimicrobial and antiviral activity against pathogens. HMOs offer many health benefits, both for infants and adults, including promoting general gut health, modulating immune function, and reducing gut inflammation in conditions such as IBD and IBS.

Also available for licensing is Glycosyn’s IP portfolio covering the use of HMOs as prebiotics, and as anti-inflammatory and anti-infective agents.

Glycosyn LLC is a US biotechnology company based in the Boston area, founded by pioneering scientists in the field of human milk oligosaccharides, that for nearly two decades has been working to engineer microorganisms for their large-scale commercial production.

###

For more details, please contact Howard Newburg, CEO, Glycosyn LLC,
at hnewburg@glycosynllc.com, or call (+1 781 884 4101‬)